With the positive developments in the early ...

At the beginning of positive developments in the 3 weeks started to decrease doses of anticonvulsant and second synchronously - further increase daily intake Lamiktala to achieve their optimal ratio, which corresponded to noticeable improvements both in terms of reductions (relief), seizures and normalize psychological functions. Often shifts toward lower affective disorders, alleviate psychopathology and dysphoric reactions, as well as improving the function of attention ahead of the actual antiepileptic effects. On the background of the effects described above, and stabilization was carried out prior to a complete cancellation of the drug, with the transfer of the patient to a secondary monotherapy Lamiktalom. There were no significant differences in the methods of adjunctive therapy Lamiktalom refractory epilepsy in adolescents biterapii was not, ie initial titration was carried out in accordance with the method described above. As known to the most frequent types of interaction Lamiktala with different anticonvulsants, depending on their pharmacokinetic characteristics, it took into account the effect of fermentoindutsiruyuschee drugs such as carbamazepine, phenytoin, barbiturates, and to accelerate the metabolism Lamiktala, and valproate, slowing down the half-life of this drug. Our own experience Lamiktalom adjunctive therapy to a variety of anticonvulsants based on a sample, prospective studies, in connection with anything of interest in the literature data on the results, double-blind, placebo-controlled studies [3,4,5,6,7,8,9]. Table 2 lists the preferred dose in terms of an initial biterapii Lamiktalom with different groups of anticonvulsants. According to our records, the right balance of doses, both in mono-and biterapii adolescents with epilepsy are allowed to avoid serious side effects, but adverse events occurred in 8% of patients of this group. This is mainly drowsiness, weakness with weakness, at least - insomnia and increased anxiety. These phenomena were stopped during a temporary dose reduction Lamiktala already at the initial stage of therapy. In neither case did not require therapy discontinuation. The overall effectiveness of treatment for patients on the above methods was 76% (complete relief or significant reduction of seizures), and poor outcomes with a decrease in seizures of less than 50% from baseline were observed in 18% and a partial reduction in the average by 25% from baseline occurred 6%. The most noticeable impact Lamiktala both in mono-and adjunctive therapy evident in the effect on cognitive function - patients improved attention, memory, increased learning ability (so, 9 boys and girls were able to enter higher education institutions). Normalizing effect has Lamiktal on adolescents with excitable traits, a tendency to protest, which was manifested in the improvement of relationships with parents and peers. It should be noted that 5 teenagers who are due to side effects on prior therapy amitriptyline latter was abolished and brought into the therapeutic schema Lamiktal, managed to arrest the anxiety and depressive symptoms and to achieve stabilization.